| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MDS1 |
| Uniprot No | Q13465 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-169aa |
| 氨基酸序列 | MRSKGRARKL ATNNECVYGN YPEIPLEEMP DADGVASTPS LNIQEPCSPA TSSEAFTPKE GSPYKAPIYI PDDIPIPAEF ELRESNMPGA GLGIWTKRKI EVGEKFGPYV GEQRSNLKDP SYGWEVHLPR SRRVSVHSWL YLGKRSSDVG IAFSQADVYM PGLQCAFLS |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MDS1重组蛋白的3篇参考文献示例(注：部分内容为模拟概括，实际文献需根据具体研究查询)：
1. **文献名称**：*"Functional characterization of recombinant MDS1-EVI1 fusion protein in myeloid leukemia"*
**作者**：Smith A, et al.
**摘要**：研究通过重组表达MDS1-EVI1融合蛋白，分析其在白血病细胞中的致癌机制，发现其通过干扰TGF-β信号通路促进细胞增殖。
2. **文献名称**：*"Expression and purification of MDS1 recombinant protein in E. coli for structural studies"*
**作者**：Zhang L, et al.
**摘要**：报道了利用大肠杆菌系统高效表达和纯化MDS1重组蛋白的方法，并通过X射线晶体学初步解析其三维结构，为功能研究提供基础。
3. **文献名称**：*"Role of MDS1 in hematopoietic differentiation: Insights from recombinant protein-mediated gene regulation"*
**作者**：Tanaka K, et al.
**摘要**：利用重组MDS1蛋白研究其在造血干细胞分化中的作用，表明MDS1通过结合特定DNA序列调控靶基因表达，影响细胞命运决定。
**注意**：以上为模拟文献，实际研究中建议通过PubMed、Web of Science等平台以关键词“MDS1 recombinant protein”或“MDS1 protein expression”检索最新文献。若研究较少，可扩展至MDS1/EVI1复合体或相关疾病(如骨髓增生异常综合征)的蛋白功能研究。
MDS1 (Myelodysplasia Syndrome 1) is a gene that encodes a transcriptional regulator, often studied in the context of its fusion with the EVI1 (Ecotropic Viral Integration Site 1) gene, forming the MDS1/EVI1 fusion protein. This genetic rearrangement is associated with hematologic malignancies, particularly myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). The recombinant MDS1 protein, engineered through molecular cloning techniques, allows researchers to dissect its structural and functional properties independent of its fusion partner.
The MDS1 protein contains conserved domains implicated in transcriptional regulation, including zinc finger motifs that mediate DNA binding and protein-protein interactions. In its native form, MDS1 is believed to act as a tumor suppressor, modulating cellular differentiation and apoptosis. However, when fused with EVI1. the resulting chimeric protein gains oncogenic potential by disrupting normal hematopoietic differentiation. Recombinant MDS1 proteins are crucial for studying these dual roles, enabling mechanistic insights into how domain-specific interactions influence cellular pathways.
Applications of recombinant MDS1 include in vitro assays to map DNA-binding sites, analyze interaction networks with co-regulators, and screen for therapeutic compounds targeting aberrant transcriptional activity. Its production typically involves expression systems like *E. coli* or mammalian cells, followed by purification via affinity chromatography. Current research focuses on understanding its role in chromatin remodeling, epigenetic regulation, and response to cellular stress, with implications for developing targeted therapies for MDS/AML. Challenges remain in resolving its full tertiary structure and context-dependent functions across different cell types.
Overall, recombinant MDS1 serves as a vital tool for unraveling the molecular pathogenesis of blood disorders and exploring precision medicine approaches.
×
